Teijin Ltd (TSE:3401)
円 1461 7 (0.48%) Market Cap: 281.32 Bil Enterprise Value: 651.12 Bil PE Ratio: 26.57 PB Ratio: 0.62 GF Score: 74/100

Teijin Ltd Regenerative Medicine Business Briefing Transcript

Dec 02, 2021 / NTS GMT
Release Date Price: 円1315 (-0.38%)
Jun Suzuki
Teijin Limited - CEO, President, Member of Advisory Board & Representative Director

This is Jun Suzuki of Teijin. Thank you for joining us in our regenerative medicine business briefing today. It gives us a great pleasure to have so many participants.

As you are aware, on January 29 of this year, Teijin announced the Board decision to acquire the shares in J-TEC through a tender offer. The stock purchase was carried out from February 1 to March 2 and was successfully completed as originally planned, making Teijin the parent company of J-TEC. Following the closing in March, we embarked on more detailed official studies on how best to improve the corporate value of both Teijin and J-TEC.

When we made the internal decision to join hands with J-TEC more than a year ago, we already had a clear vision regarding the direction of the business that is to pursue regenerative medicine using autologous cell as the alternate of tailor-made medicine. Furthermore, we did envision that this business could make the big leap through leveraging Teijin's capabilities in health care, materials

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot